INDEPENDENT THINKING. TRACEABLE EVIDENCE.Research edition · 29 October 2026
Modern DosingTHE PRACTITIONER’S PERSPECTIVEA clearer view of
the peptide economy ↗
The provider file / Dossier 33
RESEARCH DOSSIER / NOT AN ENDORSEMENT

Aurelius Health Group

A dated business research record, with the original field-level evidence labels kept intact.

Source snapshot: 2026-10-29. “Verified” below is the source dataset author’s label—not an independent license, safety, quality or clinical audit by Modern Dosing. These pages are excluded from search indexing until reviewed.
Positioning & service claimsverified

'Microdose GLP-1, done right': lower nausea, muscle preservation, planned step-down, stacked with NAD+/L-carnitine/B12; MD/DO review in 24h; $89 first month.

Audienceread

READ: side-effect-averse and performance/longevity-minded adults (testimonial 'Hansen W., 33'), skeptical of full-dose plans.

Pricing & termsverified

$89 first month, then $199/month, cancel anytime.

Clinical relationshipsverified

OpenLoop Healthcare Partners, PC and affiliates (CA, CO, NJ, WI, PR). Operator Aurelius Health, Inc.

Pharmacy & fulfillmentpartial

'Licensed US compounding pharmacy', unnamed; patient may use other pharmacy.

Advertising snapshotsnapshot

Meta US active advertiser page: ~38 results. Google US last-30-days domain search: 0 ads.

Founding yearnot_found

Not found.

    Foundersnot_found

    Not found.

      Location & entity contextnot_found

      Not found.

        Search visibility samplesnapshot

        Free domain-restricted search returned 15 result(s) in a bounded sample, not an indexed-page count; top pages listed in sources. No rank/traffic data (paid analytics excluded).

        THE MODERN DOSING WEEKLY

        The peptide news
        that changes your week.

        Evidence-backed developments. The moves that matter. What each means for your practice or business—in one weekly email.